dorzolamide actavis
teva b.v. - dorzolamidas - akių lašai (tirpalas) - 20 mg/ml - dorzolamide
dorzolamide elvim
sia elvim - dorzolamidas - akių lašai (tirpalas) - 20 mg/ml - dorzolamide
dorzolamide/timolol teva
teva pharma b.v. - dorzolamidas/timololis - akių lašai (tirpalas) - 20 mg/5 mg/ml - timolol, combinations
dorzolamide/timolol actavis
teva b.v. - dorzolamidas/timololis - akių lašai (tirpalas) - 20 mg/5 mg/ml - timolol, combinations
dorzolamide/timolol elvim
sia elvim - dorzolamidas/timololis - akių lašai (tirpalas) - 20 mg/5 mg/ml - timolol, combinations
dorzolamide/timolol ingen pharma
sia ingen pharma - dorzolamidas/timololis - akių lašai (tirpalas) - 20 mg/5 mg/ml - timolol, combinations
dorzolamide/timolol bausch [dorzolamide/timolol pharmaswiss]
bausch + lomb ireland limited - dorzolamidas/timololis - akių lašai (tirpalas) - 20 mg/5 mg/ml - timolol, combinations
lacosamide accord
accord healthcare s.l.u. - lakozamidas - epilepsija - antiepileptics, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy• in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.
lacosamide ucb
ucb pharma s.a. - lakozamidas - epilepsijos, dalinis - antiepileptics, - lacosamide ucb yra nurodyta kaip monotherapy ir adjunctive terapijos gydymo dalies pasireiškė traukuliai su ar be antrinės apibendrinimo suaugusiems, paaugliams ir vaikams nuo 4 metų amžiaus, su epilepsija.
lacosamide adroiq
extrovis eu ltd. - lakozamidas - epilepsija - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.